# Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

> **NCT02458417** · PHASE4 · COMPLETED · sponsor: **Netherlands Institute for Pigment Disorders** · enrollment: 10 (actual)

## Conditions studied

- Segmental Vitiligo
- Piebaldism

## Interventions

- **DEVICE:** ReCell
- **DEVICE:** Full surface CO2 laser 200 mJ
- **DEVICE:** Full surface CO2 laser 150 mJ
- **DEVICE:** Fractional CO2 laser 7.5 mJ, 20%

## Key facts

- **NCT ID:** NCT02458417
- **Lead sponsor:** Netherlands Institute for Pigment Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458417, "Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02458417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*